Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms

Starting soon

Conditions studied: Benign Prostate Hypertrophy(BPH)

In brief

The study aims to investigate, through the International Prostatic Symptoms Score (IPSS) questionnaire, the non-inferiority of the therapy with the alpha-blockers+Serenoa repens combination compared to the alpha-blockers+antimuscarinic combination on storage lower urinary tract syndrome (LUTS) in patients with moderate-severe symptomatic benign prostatic hyperplasia (BPH).

Key facts

Study ID

NCT07665749

Run by

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

People needed

50

Starts

2026-06-01

Expected to finish

2026-11-01

Last updated by the study team

2026-06-26

Who can join

Age: 40 and older, up to 80. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age 40-80 inclusive
• Male
• With moderate-to-severe LUTS from BPH according to IPSS score
• Placed on AB+Serenoa repens or AB+antimuscarinics for 6 months

You may not qualify if…

• Prostate or bladder cancer
• History of neurogenic bladder
• Urinary tract abnormalities (including urethral strictures)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.